NCT00861211View on ClinicalTrials.gov

Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

May 31, 2009

Conditions
Atopic Asthma
Interventions
DRUG

senicapoc

Loading Dose: 80 mg twice daily x 3 days followed by Maintenance Dose: 40 mg daily x 11 days

DRUG

Placebo

Placebo comparator

Trial Locations (2)

SE1 1YR

Guy's Drug Research Unit, London

M23 9QZ

Medicines Evaluation Unit, Manchester

Sponsors

Lead Sponsor

Icagen
All Listed Sponsors
lead

Icagen

INDUSTRY